Article Information
History
- March 15, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- An Ta, PhD1,
- Felicitas Kühne, PhD2,
- Maren Laurenz, MD2,
- Christof von Eiff, MD2,
- Sophie Warren, MS3 and
- Johnna Perdrizet, MPH4,*
- 1Cytel, United Kingdom
- 2Pfizer Pharma GmbH, Berlin, Germany
- 3Global Value and Evidence, Vaccines, Pfizer, Inc., New York, NY, USA
- 4Global Value and Evidence, Pfizer Canada, Kirkland, QC, Canada
- ↵*Correspondence details:
Johnna Perdrizet. Email: Johnna.Perdrizet{at}pfizer.com. Address: Pfizer Canada, 17300 Trans-Canada Hwy, Kirkland, QC, Canada, H9J 2M5.
Posted March 15, 2024.
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population - A German Societal Perspective Analysis
